Development and innovation

Adamed Launches New Polish Drug to Effectively Support Patients with Urological Diseases

26 June 2023

Adamed Pharma is launching its latest combination drug containing an innovative composition of solifenacin and tamsulosin, which is an important addition to the therapies available in the field of pharmacotherapy for urinary tract complaints in men caused by benign prostatic hyperplasia. Adamed Pharma has spent more than five years developing and implementing the drug, which responds to the needs of patients around the world.

Adamed Pharma began development of the combination product (modified-release tablets containing solifenacin succinate + tamsulosin hydrochloride) in July 2018. It was an in-depth analysis of patient needs for urological diseases that influenced the decision to develop the drug for such a broad patient population. Indeed, benign prostatic hyperplasia is often a very important life problem for men, negatively affecting both professional and private life. Given the widespread epidemiology of prostatic hyperplasia diseases, the composition of solifenacin with tamsulosin in oral tablet form is the subject of an international patent application of Adamed Pharma (WO2022117594).

Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate, the small gland that surrounds the male urethra. Benign prostatic hyperplasia is among the most common urological diseases in men and is age-related. According to demographic forecasts by Statistics Poland (GUS), in Poland in 2050, the share of people over the age of 65 will be as high as 32.7%[i], so in the not-too-distant future, many men will live to an age when they develop symptoms of BPH. More than 70% of men over the age of 40 are affected by lower urinary tract complaints.[ii]

The latest analysis – conducted as part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 – covered 204 countries in the years 2000-2019. It was revealed that there were 94.0 million cases of benign prostatic hyperplasia worldwide in 2019, up from 51.1 million cases in 2000 (70.5% increase in incidence). In Eastern Europe, by contrast, the percentage change in the incidence of BPH was 19.3%, with 49.9% in Poland.[iii].

We are proud of the results we have achieved in the development of our new value-added product and the process of its launch in the global market.  Thanks to the work of the Adamed Research Team and the commitment of our partners, we are introducing a therapy which has a significant impact on the lives and health of patients around the world,” says Sylwia Berdzik-Kalarus, Member of the Management Board of Adamed Pharma S.A., Director of Commercial Affairsand Business Development.

The partner involved financially in the development and implementation of this Adamed product is Adalvo, a leading B2B pharmaceutical company in Europe.

Adamed’s mission is to respond to the key challenges of contemporary medicine. As a company founded and still run by doctors, Adamed has always put the well-being of patients first. That’s why we appreciate the cooperation between Adamed and Adalvo, which is based on deep understanding of patients, their needs and expectations,” she adds.

Adamed Pharma’s R&D teams continue their R&D efforts to be able to provide patients with new innovative therapies in the future. More than 50 development projects are currently under way at various stages.


[i] Polish Agency for Enterprise Development (PARP): Aging of the Population – A Challenge for the Labour Market, Activation of 50+ Employees;

[ii] Coyne K.S., Sexton C.C., Thompson C.L. et al.: The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. Bju International. 2009;104(3):352–360

[iii] Awedew A.F., Han H., Abbasi B. et al.: The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019, The Lancet Healthy Longevity, Volume 3, Issue 11, 2022, Pages e754-e776, ISSN 2666-7568,